Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Elliott

Showing results (161-170 of 1,130) with videos related to

Pageof 113
Sort By:
Journal of the National Cancer Institute|May 1, 1987
Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomasL Elliott, W Brooks, T Roszman
Journal of Cardiovascular Pharmacology|January 1, 1994
FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. United States Food and Drug AdministrationP A Meredith, H L Elliott
Cancer|January 1, 1997
Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breastJ F Head, R L Elliott
Brain Injury|October 1, 1996
Head injury and sexual dysfunctionM L Elliott, L S Biever
Breast Cancer Research and Treatment|January 1, 1996
Comment on 'when can stereotactic core biopsy replace excisional biopsy'?J F Head, R L Elliott
Journal of the Medical Association of Georgia|February 18, 2010
When, and on what basis, do physicians decide to ignore a patient's choice in favor of administering a treatment involuntarily?Brad A Hobbs, Richard L Elliott
Virchows Archiv. A, Pathological Anatomy and Histology|June 23, 1977
Congenital lobar emphysemaH C Powell, M L Elliott
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|September 1, 1990
Concentration-effect relationships and antihypertensive mechanisms: ketanserin in the treatment of essential hypertensionH L Elliott, P A Meredith
Clinical Pharmacology and Therapeutics|June 1, 1992
An additive or synergistic drug interaction: application of concentration-effect modelingP A Meredith, H L Elliott
British Journal of Clinical Practice. Supplement|May 1, 1994
Therapeutic coverage: reducing the risks of partial complianceP A Meredith, H L Elliott
Pageof 113

Showing results (161-170 of 1,130) with videos related to

Sort By:
Pageof 113
Journal of the National Cancer Institute|May 1, 1987
Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomasL Elliott, W Brooks, T Roszman
Journal of Cardiovascular Pharmacology|January 1, 1994
FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. United States Food and Drug AdministrationP A Meredith, H L Elliott
Cancer|January 1, 1997
Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breastJ F Head, R L Elliott
Brain Injury|October 1, 1996
Head injury and sexual dysfunctionM L Elliott, L S Biever
Breast Cancer Research and Treatment|January 1, 1996
Comment on 'when can stereotactic core biopsy replace excisional biopsy'?J F Head, R L Elliott
Journal of the Medical Association of Georgia|February 18, 2010
When, and on what basis, do physicians decide to ignore a patient's choice in favor of administering a treatment involuntarily?Brad A Hobbs, Richard L Elliott
Virchows Archiv. A, Pathological Anatomy and Histology|June 23, 1977
Congenital lobar emphysemaH C Powell, M L Elliott
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|September 1, 1990
Concentration-effect relationships and antihypertensive mechanisms: ketanserin in the treatment of essential hypertensionH L Elliott, P A Meredith
Clinical Pharmacology and Therapeutics|June 1, 1992
An additive or synergistic drug interaction: application of concentration-effect modelingP A Meredith, H L Elliott
British Journal of Clinical Practice. Supplement|May 1, 1994
Therapeutic coverage: reducing the risks of partial complianceP A Meredith, H L Elliott
Pageof 113